362703-30-8

Basic information

• Product Name: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate
• Synonyms: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate;Methyl 4-Cyanotetrahydro-2H-Pyran-4-Carboxylate(WXC00765);methyl 4-cyanooxane-4-carboxylate
• CAS NO: 362703-30-8
• Molecular Formula: C₈H₁₁NO₃
• Molecular Weight: 169.17784
• Mol File: 362703-30-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(362703-30-8)
• EPA Substance Registry System: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(362703-30-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 362703-30-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and improve the efficacy of existing ones.
Used in Agrochemical Industry:
Methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate is used as an intermediate in the synthesis of agrochemicals to help develop new pesticides and other agricultural products that can enhance crop protection and yield.
Used in Perfume Industry:
Methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate is used as a component in the manufacturing of perfumes due to its strong, fruity odor, which can contribute to the creation of unique and appealing fragrances.
Used in Flavor Industry:
Methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate is used in the production of flavors for its distinctive fruity scent, which can be incorporated into various food and beverage products to enhance taste and aroma.
Used in Organic Synthesis:
Methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate is used as a versatile building block in organic synthesis for its unique properties and reactivity, allowing for the development of a wide range of organic compounds and chemical products.

Upstream product

• 111-44-4 3-oxa-1,5-dichloropentane 
• 105-34-0 methyl 2-cyanoacetate 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 

Downstream Products

• 1257044-40-8 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide 
• 130290-79-8 4-tetrahydropyranmethylamine 
• 1228779-96-1 3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 
• 848821-06-7 4-cyanotetrahydro-2H-pyran-4-carboxylic acid 
• 1010836-56-2 4-(hydroxymethyl)-tetrahydro-2H-pyran-4-carbonitrile 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 362703-32-0 4-{[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-methyl}-tetrahydro-pyran-4-carboxylic acid methyl ester 

Relevant articles and documents

NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9

The present invention relates to an inhibitor of cyclin-dependent kinase CDK9, having a structure of formula (I). The present invention also provides a method of treating a cancer of a precancerous condition related to CDK9 activity with the inhibitor and a use of the same.

PROCESS FOR THE PREPARATION OF VENETOCLAX

The present disclosure provides novel synthetic process for the preparation of venetoclax. The disclosed processes involve the use of novel intermediates. Processes for the preparation of these intermediates are also disclosed as well as methods for the preparation of particularly useful salts thereof.

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor

Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300–10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

Synthesis and structure-activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

A novel series of achiral TNF-α converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-α production in an LPS-stimulated whole blood assay with an IC5

Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha

The present application describes novel β-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3